CN101439031A - 一种含18种氨基酸的药物组合物 - Google Patents
一种含18种氨基酸的药物组合物 Download PDFInfo
- Publication number
- CN101439031A CN101439031A CNA2008101880357A CN200810188035A CN101439031A CN 101439031 A CN101439031 A CN 101439031A CN A2008101880357 A CNA2008101880357 A CN A2008101880357A CN 200810188035 A CN200810188035 A CN 200810188035A CN 101439031 A CN101439031 A CN 101439031A
- Authority
- CN
- China
- Prior art keywords
- amino acids
- pharmaceutical composition
- acid
- injection
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 229940024606 amino acid Drugs 0.000 claims abstract description 67
- 235000001014 amino acid Nutrition 0.000 claims abstract description 67
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000002347 injection Methods 0.000 claims abstract description 42
- 239000007924 injection Substances 0.000 claims abstract description 42
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 38
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 27
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 25
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 24
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 24
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 24
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 24
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 24
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 24
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 24
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 24
- -1 compound amino acid Chemical class 0.000 claims abstract description 24
- 229960003067 cystine Drugs 0.000 claims abstract description 24
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 24
- 239000004220 glutamic acid Substances 0.000 claims abstract description 24
- 235000014705 isoleucine Nutrition 0.000 claims abstract description 24
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000310 isoleucine Drugs 0.000 claims abstract description 24
- 235000005772 leucine Nutrition 0.000 claims abstract description 24
- 235000006109 methionine Nutrition 0.000 claims abstract description 24
- 229930182817 methionine Natural products 0.000 claims abstract description 24
- 235000002374 tyrosine Nutrition 0.000 claims abstract description 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000014393 valine Nutrition 0.000 claims abstract description 24
- 239000004474 valine Substances 0.000 claims abstract description 24
- 239000004475 Arginine Substances 0.000 claims abstract description 23
- 239000004471 Glycine Substances 0.000 claims abstract description 23
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 23
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 23
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 23
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004473 Threonine Substances 0.000 claims abstract description 23
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 claims abstract description 23
- 235000004279 alanine Nutrition 0.000 claims abstract description 23
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000014304 histidine Nutrition 0.000 claims abstract description 23
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960005357 lysine acetate Drugs 0.000 claims abstract description 23
- 235000013930 proline Nutrition 0.000 claims abstract description 23
- 235000004400 serine Nutrition 0.000 claims abstract description 23
- 235000008521 threonine Nutrition 0.000 claims abstract description 23
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 20
- 235000008729 phenylalanine Nutrition 0.000 claims abstract description 20
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 183
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 118
- 229910052757 nitrogen Inorganic materials 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 23
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 19
- 239000008215 water for injection Substances 0.000 claims description 18
- 238000009413 insulation Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 16
- 238000007689 inspection Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000002614 leucines Chemical class 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 44
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 abstract description 31
- 230000003078 antioxidant effect Effects 0.000 abstract description 15
- 239000003963 antioxidant agent Substances 0.000 abstract description 14
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract description 5
- 244000248349 Citrus limon Species 0.000 abstract 1
- 235000005979 Citrus limon Nutrition 0.000 abstract 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 description 21
- 229960002433 cysteine Drugs 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002834 transmittance Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 8
- 235000010262 sodium metabisulphite Nutrition 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 239000000654 additive Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000006864 oxidative decomposition reaction Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 229910021655 trace metal ion Inorganic materials 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000272173 Calidris Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical class OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
检测项目 | 标准指标 | 0月 | 1月 | 2月 | 3月 | 6月 |
PH值 | 应为5.0—6.2 | 5.74 | 5.74 | 5.74 | 5.74 | 5.73 |
性状 | 几乎无色的澄明液体 | 合格 | 合格 | 合格 | 合格 | 合格 |
透光率 | 不得低于95% | 99.0% | 99.0% | 99.0% | 99.0% | 89.8% |
门冬氨酸 | 标示量85—115% | 92.0% | 92.0% | 92.0% | 91.9% | 91.7% |
谷氨酸 | 标示量85—115% | 108.0% | 108.0% | 108.0% | 108.0% | 107.9% |
丝氨酸 | 标示量85—115% | 95.8% | 95.8% | 95.8% | 95.8% | 95.7% |
精氨酸 | 标示量85—115% | 95.5% | 95.5% | 95.5% | 95.5% | 95.3% |
甘氨酸 | 标示量85—115% | 92.6% | 92.6% | 92.5% | 92.1% | 92.0% |
苏氨酸 | 标示量85—115% | 93.6% | 93.6% | 93.6% | 93.5% | 93.2% |
脯氨酸 | 标示量85—115% | 90.7% | 90.7% | 90.7% | 90.7% | 90.5% |
丙氨酸 | 标示量85—115% | 103.8% | 103.8% | 103.8% | 103.8% | 103.8% |
缬氨酸 | 标示量85—115% | 88.4% | 88.4% | 88.3% | 88.1% | 88.0% |
蛋氨酸 | 标示量85—115% | 110.0% | 110.0% | 110.0% | 110.0% | 110.0% |
异亮氨酸 | 标示量85—115% | 96.4% | 96.4% | 96.4% | 96.2% | 96.0% |
亮氨酸 | 标示量85—115% | 102.1% | 102.1% | 102.1% | 102.1% | 102.0% |
色氨酸 | 标示量85—115% | 89.1% | 89.1% | 88.9% | 88.8% | 88.7% |
组氨酸 | 标示量85—115% | 93.0% | 93.0% | 93.0% | 92.8% | 92.5% |
苯丙氨酸 | 标示量85—115% | 92.0% | 92.0% | 91.9% | 91.7% | 91.6% |
赖氨酸醋酸盐 | 标示量85—115% | 93.3% | 93.3% | 93.3% | 93.3% | 93.1% |
酪氨酸 | 标示量80—120% | 90.0% | 90.0% | 89.8% | 89.7% | 89.5% |
胱氨酸 | 标示量80—120% | 101.0% | 100.9% | 100.9% | 100.7% | 100.4% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101880357A CN101439031B (zh) | 2008-12-29 | 2008-12-29 | 一种含18种氨基酸的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101880357A CN101439031B (zh) | 2008-12-29 | 2008-12-29 | 一种含18种氨基酸的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101439031A true CN101439031A (zh) | 2009-05-27 |
CN101439031B CN101439031B (zh) | 2010-12-15 |
Family
ID=40723731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101880357A Active CN101439031B (zh) | 2008-12-29 | 2008-12-29 | 一种含18种氨基酸的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101439031B (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101933922A (zh) * | 2010-09-08 | 2011-01-05 | 郑飞雄 | 一种含新抗氧化剂的氨基酸组合物 |
CN102145009A (zh) * | 2010-12-29 | 2011-08-10 | 山东鲁抗辰欣药业有限公司 | 一种十八复方氨基酸注射液及其制备方法 |
CN102600139A (zh) * | 2012-02-28 | 2012-07-25 | 郑飞雄 | 一种含20种氨基酸的药物组合物 |
CN102743379A (zh) * | 2012-07-30 | 2012-10-24 | 李慧 | 一种含十八种氨基酸的组合物 |
CN102861011A (zh) * | 2012-10-12 | 2013-01-09 | 杜博 | 18种氨基酸的药物组合物及制剂 |
CN102940628A (zh) * | 2012-10-10 | 2013-02-27 | 八峰药化宜昌有限责任公司 | 一种复方氨基酸注射液及其制备方法 |
CN103622996A (zh) * | 2013-10-28 | 2014-03-12 | 湖北一半天制药有限公司 | 3%氨基酸3%甘油电解质注射液的制备方法 |
CN103638018A (zh) * | 2013-12-03 | 2014-03-19 | 辽宁海思科制药有限公司 | 一种复方氨基酸注射液18aa-ⅶ药物组合物及其制备方法 |
CN105079010A (zh) * | 2014-05-21 | 2015-11-25 | 刘力 | 复方氨基酸注射液18aa的药物组合物和用途 |
CN105311019A (zh) * | 2014-05-27 | 2016-02-10 | 刘力 | 复方氨基酸注射液18aa-v的药物组合物和用途 |
CN106596323A (zh) * | 2016-12-13 | 2017-04-26 | 宜昌三峡制药有限公司 | 速溶支链氨基酸质量标准 |
CN109381423A (zh) * | 2017-08-09 | 2019-02-26 | 湖北半天制药有限公司 | 一种含19种氨基酸的药物组合物及其制备方法 |
CN109381460A (zh) * | 2017-08-09 | 2019-02-26 | 湖北半天制药有限公司 | 一种含18种氨基酸的药物组合物及其制备方法 |
-
2008
- 2008-12-29 CN CN2008101880357A patent/CN101439031B/zh active Active
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101933922A (zh) * | 2010-09-08 | 2011-01-05 | 郑飞雄 | 一种含新抗氧化剂的氨基酸组合物 |
CN101933922B (zh) * | 2010-09-08 | 2013-01-30 | 郑飞雄 | 一种含抗氧化剂的氨基酸组合物 |
CN102145009A (zh) * | 2010-12-29 | 2011-08-10 | 山东鲁抗辰欣药业有限公司 | 一种十八复方氨基酸注射液及其制备方法 |
CN102600139A (zh) * | 2012-02-28 | 2012-07-25 | 郑飞雄 | 一种含20种氨基酸的药物组合物 |
CN102600139B (zh) * | 2012-02-28 | 2015-10-14 | 郑飞雄 | 一种含20种氨基酸的药物组合物 |
CN102743379A (zh) * | 2012-07-30 | 2012-10-24 | 李慧 | 一种含十八种氨基酸的组合物 |
CN102743379B (zh) * | 2012-07-30 | 2013-07-31 | 李慧 | 一种含十八种氨基酸的组合物及其制备方法 |
CN102940628A (zh) * | 2012-10-10 | 2013-02-27 | 八峰药化宜昌有限责任公司 | 一种复方氨基酸注射液及其制备方法 |
CN102861011B (zh) * | 2012-10-12 | 2014-11-05 | 杜博 | 18种氨基酸的药物组合物及制剂 |
CN102861011A (zh) * | 2012-10-12 | 2013-01-09 | 杜博 | 18种氨基酸的药物组合物及制剂 |
CN103622996A (zh) * | 2013-10-28 | 2014-03-12 | 湖北一半天制药有限公司 | 3%氨基酸3%甘油电解质注射液的制备方法 |
CN103622996B (zh) * | 2013-10-28 | 2016-07-06 | 湖北一半天制药有限公司 | 3%氨基酸3%甘油电解质注射液的制备方法 |
CN103638018A (zh) * | 2013-12-03 | 2014-03-19 | 辽宁海思科制药有限公司 | 一种复方氨基酸注射液18aa-ⅶ药物组合物及其制备方法 |
CN103638018B (zh) * | 2013-12-03 | 2015-06-03 | 辽宁海思科制药有限公司 | 一种复方氨基酸注射液18aa-ⅶ药物组合物及其制备方法 |
CN105079010A (zh) * | 2014-05-21 | 2015-11-25 | 刘力 | 复方氨基酸注射液18aa的药物组合物和用途 |
CN105311019A (zh) * | 2014-05-27 | 2016-02-10 | 刘力 | 复方氨基酸注射液18aa-v的药物组合物和用途 |
CN106596323A (zh) * | 2016-12-13 | 2017-04-26 | 宜昌三峡制药有限公司 | 速溶支链氨基酸质量标准 |
CN109381423A (zh) * | 2017-08-09 | 2019-02-26 | 湖北半天制药有限公司 | 一种含19种氨基酸的药物组合物及其制备方法 |
CN109381460A (zh) * | 2017-08-09 | 2019-02-26 | 湖北半天制药有限公司 | 一种含18种氨基酸的药物组合物及其制备方法 |
CN109381460B (zh) * | 2017-08-09 | 2023-09-01 | 湖北一半天制药有限公司 | 一种含18种氨基酸的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101439031B (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101439031B (zh) | 一种含18种氨基酸的药物组合物 | |
CN101439036B (zh) | 一种含18种氨基酸的药物组合物 | |
CN101357118B (zh) | 一种含15种氨基酸的药物组合物及其制备方法 | |
CN101933922B (zh) | 一种含抗氧化剂的氨基酸组合物 | |
CN102626409B (zh) | 一种含18种氨基酸的药物组合物 | |
CN101455631B (zh) | 环磷腺苷葡胺注射液及其制备工艺 | |
CN103315997A (zh) | 一种含18种氨基酸的药物组合物 | |
CN102743379B (zh) | 一种含十八种氨基酸的组合物及其制备方法 | |
WO2022222630A1 (zh) | 一种复方电解质注射液及其制备方法 | |
CN103315998A (zh) | 一种含18种氨基酸的药物组合物 | |
CN104840418A (zh) | 一种盐酸法舒地尔注射液组合物及其制备方法 | |
CN101791315B (zh) | 复方甘草酸单铵s药物组合物及其大容量注射剂制备方法 | |
CN102525893B (zh) | 盐酸去氧肾上腺素注射液及其制剂工艺 | |
CN102940628A (zh) | 一种复方氨基酸注射液及其制备方法 | |
CN102600139B (zh) | 一种含20种氨基酸的药物组合物 | |
CN102743378B (zh) | 一种含十八种氨基酸的组合物 | |
CN1270702C (zh) | 辅酶q10静脉输液及其制备方法 | |
CN109381460B (zh) | 一种含18种氨基酸的药物组合物及其制备方法 | |
CN110314132B (zh) | 一种门冬氨酸鸟氨酸注射液及其制备方法 | |
CN1813674A (zh) | 一种用于静脉给药的维生素c钠制剂及其制备方法 | |
CN102552251B (zh) | 一种含17种氨基酸的药物组合物 | |
CN102204908B (zh) | 一种含依达拉奉化合物的药物组合物及其制备方法 | |
CN102357094A (zh) | 18种氨基酸药物组合物 | |
CN101664385B (zh) | 富马酸伊布利特注射液及其制备方法 | |
CN103622996B (zh) | 3%氨基酸3%甘油电解质注射液的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: BAFENG PHARMACEUTICALS & CHEMICALS YICHANG Co.,Ltd. Assignor: Zheng Feixiong Contract record no.: 2012350000034 Denomination of invention: Pharmaceutical composition containing 18 kinds of amino acids Granted publication date: 20101215 License type: Common License Open date: 20090527 Record date: 20120405 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20231029 Address after: No. 39 Dongchengbian Street, Wenquan Street, Gulou District, Fuzhou City, Fujian Province (at the intersection of Dongchengbian Street and Wenquan Branch Road), 15th Floor, 04 Business Office-1, Building 1, Hengyu International, 350000 Patentee after: Fujian fengkaisi Investment Co.,Ltd. Address before: Room 15-506, Huqian Community, Gulou District, Fuzhou City, Fujian Province, 350003 Patentee before: Zheng Feixiong |
|
TR01 | Transfer of patent right |